Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: In Vitro & In Vivo Diagnostic Substances.
The next scheduled catalyst is A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria on October 15, 2026. There are 6 upcoming events on record.
Cash runway is approximately 32.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 36 concluded trials, 75% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Trial Milestone | Phase 3 |
| October 15, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Trial Milestone | Phase 3 |
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 15, 2027 | A Study of CDX-622 in Participants With Mild to Moderate Asthma | Trial Milestone | Phase 1 |
| June 15, 2028 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) | Trial Milestone | Phase 3 |
| September 15, 2028 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Trial Milestone | Phase 3 |
Track CLDX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CLDX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.